Myopia is generally what happens when unprecedented opportunities are placed before them. Those in the know generally do better than those in the worry. Consider Cetus, a startup biotech with a focus on a liver drug. The FDA delayed the approval of the drug, and a major funding crisis ensued. Chiron offered to take over the liabilities contingent on the sale of two patents (# 4,683,202 and # 4,683,195) to a third party, Roche Molecule for $300M (in 1993). This sale was stalled because DuPont challenged the validity of the patents, based on the formal claims written by the inventor (not a patent attorney), Kary Mullis. In the end, the soap opera turned out well for the investors with weak constitutions. For $300M, they sold the two patents to Roche, turned the company over to Chiron, and walked away. Kary Mullis won the Nobel prize for his invention embedded in these two patents, known as polymerase chain reaction (PCR) which allows DNA to be cloned. Over 4000 patents in biotech cite these original two patents. In our estimation, $300M represents "pennies on the dollar" valuation of these patents. The shareholders got a payday, and left the game. Roche on the other hand is thriving based on its intangible assets. Let IPstreet.com assist you.

In Nortel's recent bankrupcy, the liquidation of the IP assets led to a bidding war. Google offered $900M for the patents; Apple and Microsoft created an alliance (with RIM, Sony, EMC, Ericsson) to offer $4.5B for the same patents^. Certainly there was a great disparity in these bid prices. How can you objectively determine the value of a portfolio and patent duration. Let the tools at IPstreet.com help you.

Traditionally, IP counselors are buffered from the senior-executive decision-making process. Although patent attorneys represent an elite group that have a scientific background, this technical background many times prevents you from being a part of top-level strategic decisions. With your subject-matter expertise, and our ability to convert the complexities of the patent space into actionable business intelligence, you can earn a seat in the executive board room. Connie from Lee & Hayes says, " As an IP attorney, I specialize in life sciences technologies and need tools that go beyond a good search. I use IP Street's suite of tools because the analysis provides great business insights in a fraction of the time it used to take, allowing me to be more responsive to my clients with better information. As a result, I am able to play a more integral role in my clients' business. " It is about time you can communicate actionable business intelligence from patent documents. Executives are starting to recognize the importance of Intellectual Assets and their management, but they need more. An you can provide it for them.

Knowledge is power in developing and implementing strategy. Ignorance is not a defense nor an excuse in attempts to navigate the IP landscape. Utilizing our tools, we can help you understand more about your patent portfolios so that you can executive better business strategies.

Historically, commercial use of university research has been viewed in terms of spillovers. Recently, there has been a dramatic increase in technology transfer through licensing as universities attempt to appropriate the returns from faculty research. This change has prompted concerns regarding the source of this growth—specifically, whether it suggests a change in the nature of university research. (Thursby 2002) ^ University-based firms are receiving growing interest from policy makers and researchers. Such firms obtain a variety of tangible and intangible resources from their academic partners, and are expected to translate these advantages into substantial gains. (Bonardo 2011) ^Technology transfer is a big concern for universities, how can they identify business opportunities from IP developed? We have created relationships with universities to help them do just that. Contact us to learn more.